Damora Therapeutics, Inc.

For the period ended Jun 30, 2026. Filed Aug 10, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 10, 2026

DMRA$24.15+0.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Changes in Stockholders’ Equity

(in thousands, except share amounts)

Mezzanine Equity · Stockholders’ Equity
Three Months Ended June 30, 2025 · Preferred Stock · Series B Non-Voting Convertible Preferred Stock · Series C Non-Voting Convertible Preferred Stock · Common Stock · AdditionalPaid-In · Accumulated · AccumulatedOtherComprehensive · TotalStockholders’
Shares · Amount · Shares · Amount · Shares · Amount · Shares · Amount · Capital · Deficit · Income (Loss) · Equity
Balance at March 31, 2025	161	1,360		—	—	—	—	1,322,359	—	292,106	(280,057)	300	13,709
Stock-based compensation expense	—	—		—	—	—	—	—	—	172	—	—	172
Conversion of Series A Preferred Stock	(2)	(19)		—	—	—	—	2,201	—	19	—	—	—
Other comprehensive income, net	—	—		—	—	—	—	—	—		—	509	509
Net loss	—	—		—	—	—	—	—	—	—	(3,437)	—	(3,437)
Balance at June 30, 2025	159	$1,341		—	$—	—	$—	1,324,560	$—	$292,297	$(283,494)	$809	$10,953
Mezzanine Equity · Stockholders’ Equity
Three Months Ended June 30, 2026	Preferred Stock		Series B Non-Voting Convertible Preferred Stock	Series C Non-Voting Convertible Preferred Stock	Common Stock	AdditionalPaid-In	Accumulated	AccumulatedOtherComprehensive	TotalStockholders’
Shares · Amount · Shares · Amount · Shares · Amount · Shares · Amount · Capital · Deficit · Income (Loss) · Equity
Balance at March 31, 2026	159	1,341		16,366	117,621	1,877	13,490	60,303,212	1	893,542	(515,146)	754	511,603
Stock-based compensation expense	—	—		—	—	—	—	—	—	6,144	—	—	6,144
Conversion of Series A preferred shares to Common Stock	(159)	(1,341)		—	—		—	158,361	—	1,341	—	—	—
Conversion of Series C Preferred Stock issued in connection with the asset acquisition of Damora Therapeutics, Inc	—	—		—	—	—	—	—	—	—	—	—	—
Issuance of common stock in connection with vesting of restricted stock units	—	—		—	—	—	—	726	—	—	—	—	—
Exercise of stock options	—	—		—	—	—	—	31,902	—	226	—	—	226
Forfeiture of shares	—	—		—	—	(155)	(1,114)	—	—	1,114	—	—	—
Other comprehensive income, net	—	—		—	—	—	—		—	—	—	(22)	(22)
Proceeds from At-the-Market facility	—	—		—	—	—	—	1,240,400	—	29,282	—	—	29,282
Net loss	—	—		—	—	—	—	—	—	—	(31,174)	—	(31,174)
Balance at June 30, 2026	—	$—		16,366	$117,621	1,722	$12,376	61,734,601	$1	$931,649	$(546,320)	$732	$516,059

Mezzanine Equity · Stockholders’ Equity
Six Months Ended June 30, 2025 · Preferred Stock · Series B Non-Voting Convertible Preferred Stock · Series C Non-Voting Convertible Preferred Stock · Common Stock · AdditionalPaid-In · Accumulated · AccumulatedOtherComprehensive · TotalStockholders’
Shares · Amount · Shares · Amount · Shares · Amount · Shares · Amount · Capital · Deficit · Income (Loss) · Equity
Balance at December 31, 2024	161		1,360			—		—		—		—		1,316,989		—		291,898		(277,524)		97		15,831
Stock-based compensation expense	—		—			—		—		—		—		—		—		351		—		—		351
Conversion of Series A Preferred Stock	(2)		(19)			—		—		—		—		2,201		—		19		—		—		—
Issuance of common stock in connection with vesting of restricted stock units	—		—			—		—		—		—		5,370		—		29		—		—		29
Other comprehensive income, net	—		—			—		—		—		—		—		—				—		712		712
Net loss	—		—			—		—		—		—		—		—		—		(5,970)		—		(5,970)
Balance at June 30, 2025	159		$1,341			—		$—		—		$—		1,324,560		$—		$292,297		$(283,494)		$809		$10,953
Mezzanine Equity · Stockholders’ Equity
Six Months Ended June 30, 2026	Preferred Stock			Series B Non-Voting Convertible Preferred Stock		Series C Non-Voting Convertible Preferred Stock		Common Stock		AdditionalPaid-In		Accumulated		AccumulatedOtherComprehensive		TotalStockholders’
Shares · Amount · Shares · Amount · Shares · Amount · Shares · Amount · Capital · Deficit · Income (Loss) · Equity
Balance at December 31, 2025	159		1,341			16,366		117,621		43,882		297,291		1,597,321		—		310,688		(487,363)		802		240,380
Stock-based compensation expense	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	9,278	—	—	—	—	—	9,278
Conversion of Series A preferred shares to Common Stock	(159)		(1,341)			—		—		—		—		158,361		—		1,341		—		—		—
Conversion of Series C Preferred Stock issued in connection with the asset acquisition of Damora Therapeutics, Inc	—		—			—		—		(2,364)		(16,990)		2,364,000		—		16,990		—		—		—
Stockholder approval of the issuance of common stock upon conversion of Series C non-voting convertible preferred stock	—		—			—		—		(39,641)		(266,811)		39,641,000		1		266,810		—		—		—
Issuance of common stock in connection with offering, net of issuance costs of $20,753	—		—			—		—		—		—		16,644,737		—		295,497		—		—		295,497
Forfeiture of shares	—		—			—		—		(155)		(1,114)		(9,638)		—		1,114		—		—		—
Issuance of common stock in connection with vesting of restricted stock units												—		6,018				—						—
Exercise of stock options	—		—			—		—		—		—		92,402		—		649		—		—		649
Other comprehensive income, net	—		—			—		—		—		—				—				—		(70)		(70)
Proceeds from At-the-Market facility, net of issuance costs of $688	—		—			—		—		—		—		1,240,400		—		29,282		—		—		29,282
Net loss	—		—			—		—		—		—		—		—		—		(58,957)		—		(58,957)
Balance at June 30, 2026	—		$—			16,366		$117,621		1,722		$12,376		61,734,601		$1		$931,649		$(546,320)		$732		$516,059

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.